Valerio Therapeutics acquires Emglev Therapeutics

Valerio Therapeutics, a company focused on DNA Decoy therapeutics, has recently acquired Emglev Therapeutics, a firm known for its development of single-domain antibody (sdAb) based treatments. This acquisition is expected to significantly bolster Valerio’s capabilities in drug development across various therapeutic areas.

Emglev Therapeutics originated from Institut Curie and has created synthetic single-domain antibody libraries that overcome the challenges associated with traditional antibody discovery methods. These libraries allow for the in vitro identification of humanized or fully human sdAbs, providing a notable advantage in the field of antibody development.

Dr. Shefali Agarwal, the President and CEO of Valerio Therapeutics, expressed enthusiasm about the acquisition. She highlighted that the integration of Emglev Therapeutics into Valerio’s newly formed subsidiary, Valour Bio, underscores their commitment to introducing innovative therapeutics to patients. Dr. Agarwal emphasized the potential of Emglev’s advanced technology, which was developed by their accomplished scientists, to yield novel treatments such as sdAb drugs, radio-conjugates, bispecific T-cell engagers, blocking and binding sdAbs, and CAR-T sdAb drugs.

Emglev’s sdAb technology, which has already been humanized, offers several advantages including a faster development process and reduced immunogenicity risks. This technology has broad applications in treating autoimmune diseases, inflammatory disorders, and cancer. It supports the development of various treatment modalities including drug and radio-conjugates, CAR-T sdAb drugs, and bispecific T-cell engagers.

Preclinical proof-of-concept studies have demonstrated the efficacy of Emglev’s technology with CAR-T sdAb, BiTE sdAb, and sdAb-drug conjugates, highlighting the company’s capability to discover customized antibody fragments. Emglev Therapeutics’ CEO Christelle Masdeu commented on the acquisition, noting that as a shareholder of Valour Bio, they are dedicated to channeling their energy, expertise, and passion into developing unique treatments that address unmet medical needs. She also mentioned that the synergy between Emglev’s proprietary synthetic single-domain antibody platform and Valerio’s preclinical and clinical development expertise aligns perfectly with their mission to deliver transformative therapies that significantly improve patient outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!